Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3% polidocanol foam vs diluent for Grade I–III bleeding internal hemorrhoids
ChiCTR2400088702Phase 4Not yet recruiting
- Sponsor
- Third People's Hospital of Chengdu
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of 10XB101 in internal hemorrhoid and hemorrhoid (2 arms), sponsored by Third People's Hospital of Chengdu. Primary endpoints: Effectiveness of treatment on bleeding control, Effectiveness of prolapse improvement and 1 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
10XB101
03
Conditions
internal hemorrhoidhemorrhoid
Beyond the preview
Go deeper on ChiCTR2400088702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088702.